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The iast decade has witnessed enormous progress of protein inhibitors of cysteine proteinases concerning their structures, functions and evolutionary 
relationships. Although they differ in their molecular properties and biological distribution, they are structurally related proteins. All three inhibi- 
tory families, the stetins, the cystatins and the kininogens, are members of the same superfamily. Recently determined crystal structures of chicken 
cystatin and human stefin B established a new mechanism of interaction between cysteine proteinases and their inhibitors which is fundamentally 
different from the standard mechanism for serine proteinases and their inhibitors. 
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1. INTRODUCTION 
During the last decade, our understanding of cellular 
processes involving protein degradation has reached the 
level at which we can explain with more certainty the 
regulation and mechanism controlling proteinase ac- 
tivities. Among four classes of proteinases, the aspartic, 
the serine, the metallo and cysteine proteinases, more 
recently attention has been paid to the last group of en- 
zymes of mammalian origin. Current evidence suggests 
that lysosomal cysteine proteinases cathepsins B, H, L 
and S are papain-like enzymes. They are well- 
characterized proteins (reviewed in [I ,2]) with known 
primary structures 13-71. Very recently, the crystal 
structure of human liver cathepsin B has been solved by 
X-ray crystallography indicating that the overall 
folding pattern of this enzyme and the arrangement of 
the active-site residues are similar to the related cysteine 
proteinases papain and actinidin [Q. 
Within the last ten years it also has become evident 
that newly discovered protein inhibitors of cysteine pro- 
teinases, named cystatins, offer a new insight into the 
processes in which the inhibitors participate (reviewed 
in [9, lo]). These inhibitors might protect the cells from 
inappropriate endogenous or external proteolysis 
and/or could be involved in the control mechanism 
responsible for intracellular or extracellular protein 
breakdown. The cystatins are tight and reversibly bin- 
ding inhibitors of the papain-like cysteine proteinases. 
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They form a superfamily of sequentially homologous 
proteins subdivided into three families, the stefins, the 
cystatins and the kininogens [ll]. The recently 
discovered cathelin, a protein inhibitor of cathepsin L, 
indicates that a new family of cysteine proteinase in- 
hibitors may exist [12]. 
In this minireview it is impossible to cite all of the 
authors who have contributed information to the pre- 
sent status of cystatins. Therefore, additional 
references will be found in reviews cited in this paper. 
This minireview will stress some of the more important 
features of cystatins including their recently determined 
structures and the proposed mechanism of interaction 
with their target enzyines. 
2. STEFIN FAMILY 
The protein inhibitors of this family are single-chain 
proteins with Mr of about 11 000, which lack disulfide 
bonds and carbohydrates [9]. Human stefin A and rat 
cystatin cy are found in high concentrations in various 
types of epithelial cells and in polymorphonuclear 
leucocytes. In contrast, human stefin B and rat cystatin 
/3 are found to be widely distributed amongst different 
cells and tissues [2,9,13]. Although it was suggested that 
stefins are intracellular proteins, they have been found 
also in extracellular fluids 1141. The stefins have been 
isolated from different mammalian tissues including 
humans, and characterized. Whereas human stefin A 
occurs in multiple isoelectric forms, with p1 values in 
the range 4.5-5.0 [9,15,16], human stefin B is a more 
neutral protein with pl values in the range 5.9-6.5 
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[9,17]. Stefins are stable in the neutral and alkaline PI-I 
range as well as heat stable. I-Iuman stefin I3 forms 
disulfide-linked dimers with iWr of about 25 000. The 
dimeric form is inactive and can be converted to the in- 
hibitory active monomer under reducing conditions 
[17]. Dimeric bond formation is consistent with similar 
observation for rat cystatin p [ 181. It has been suggested 
that the inhibitory activity of rat cystatin p can be 
regulated with covalent modification by forming a mix- 
ed disulfide with glutathione. Residue Cys-3 of rat 
cystatin @ is involved in the binding of glutathione in 
such a manner that the free form of the inhibitor is ac- 
tive and the complex with glutathione is inactive 
[l&19]. 
ed in E. coli [20,2 I] and the resulting recombinant stefin 
A exhibits &nilar~biochemicaI properties as the native 
protein. Also a gene coding for human stefin B was syn- 
thesized and expressed [22,23]. In order to avoid oxida- 
tion of Cys-3 which causes dimer formation, the mutant 
[Ser3]stefin B was prepared and the resulting recombi- 
nant protein was used for determination of the crystal 
structure of stefin B in a complex with papain [24]. 
Stefins are potent reversible and competitive in- 
hibitors of cysteine proteinases. The inhibition constant 
for papain with human stefin A is 1.9 x lo-” M. 
Cathepsin B inhibition (7.3 x IO-’ M) is weaker than 
that for papain, cathepsin I-I and cathepsin L. 
Recently, a stretch of DNA containing the coding se- 
quence for human stefin A was synthesized and express-, 
1 2 3 4 5 6 
In addition to stefins of animal origin, in rice there 
are two different inhibitors of cysteine proteinases, 
designated as oryzacystatin I and II [25,26]. Besides pa- 
pain and other cysteine proteinases [25] oryzacystatin 
also inhibits insect digestive cysteine proteinases [27]. 
Both p!ant inhibitors do not contain cysteine (see Fig. 
l), similar to other members of the stefin family. 
Although it was originally proposed that oryzacystatins 
represent a new photocystatin family [26], both the rice 
inhibitors should be included at least temporarily in the 
stefin family. The photostefins may act as host plant 
resistance factors for insects and other agricultural 
pests. 
7 6 9 10 11 
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
Stefin family 
hse #IPGGL~--~SEAKPAlPEIOEIVDIVDKVKPQLSEKl~ElV--GKLEAVOVKlOVVAGlNVV~-lKVRAGD ---~--.---------~-----~------WRPRHL-KVFKSLPGONEDLVLlGVOVOkNKDDELlGF 
rse acHDPG-lYGIVGQV~---SEAKPAYPEIGEVADKVKRQLEEKYNSKV--EKFKVVEVKSOVVAGOILF--HKVDVGN-~-~--~-----~-~-~~-~-~~-*~~--- GRFLHH-KVLRGLSGOD*DLKLLDVOYNKYKNDELYDF 
Rsb osWRCGAP~---SAYOPAYAEYOHtAOOVRSOLEEKVNKKF--PVFKAVSFKSOVVASYNVF--IKVHVGD--- ~--~---------~----~~-------EDFVHL-RVFPSLPHEUKPLYLSNVOlNKAKHDELYYF 
rsb ecWHCGAP~---SAlWPAYIEIOElAOKVKSGLEEKANGKF--SVFKAISFRRQVVAGYNFF--lKVDV~E-~-~--~-----~-~-~-~--~~------- EYCVHL-RVFEPLPHENKPLYLSSVOlDKEKHDELTYF 
ore, RSSDGGPVLGGV'--EPVGNENDLWLVDLARFAVY~HNKKANSLL--~FEKLVSVKO9VVAGYLYVFTlEVKEGD--- ~--~-------~-~~----'-------AKKLV~AKVWEK-PWHOFKELOEFKPVDASANA 
arc11 HAlSAOSMAPEGGRHPROPAGKENOLYlV~LARFAVA~~NSKANAML--ELSRVVKVROOVVGSFHHVLTVEVKEPGG--~--~-----~-~-~--------~---- ANKLYEAKVVER-AWENFKOLODFKPLOAYA 
Cystatin family 
drc IAlOAADEQVVGGV----SOLEGDSRKEALELLDAYLAQLAYGDGPSV-KAlNVlSVYGOVVAGSLNY~-VEVEL-DNGSD --~-------~-~-----'--~---KK-OClV-KlUYQ-PWLKENGYNIKlKCSQDDGELDRYU 
s)Bc QCVGCP~--.SEVKGDKLKOSEElLNKSLSKLAAGD6PTV-KLVKlNSAYlOVVSGSKDV--lNADL~KDENO--~ -------~-~----~-------KYKTCDl-YlUSQ-PWLENGlEVY~FNCPGEPKVVKKWSA 
cc SEDRSRL1GAP~---VPVDENOEGLORALOFAHAEVNRASNDKVSSRVVRVlSAKROLVSGlKVl~-LQVElGRYYCPKGSGDL~- ----QSCEFHDEPEHA-KVYYCYF-VVVSI-PWL-NOIKLLESKC-0 
hcc SSPGKPPRLVGGP~---WDASVE6EGVRRALDFAVQEYMKASNDMY~5RALOVVRARKOlVAGVNVF~-LDVELGRllClKlQPNL ------DNC FHDOPHLK-RKAFCSF-OIVAV.PWO-GTMTLSKSYC-QDA 
Rcs SSSKEENRIlPGGl~---VDADLWDEWVORAL~IFAlSEVNKAlEDEY'IRRPLOVLRAREOlFGGVNVF~-FDVEVGRllClKSQPNL- -----DlCAFHEQPELO-KKOLCSF-EVYEV-BVE-DRNSLVDSRC-OEA 
hsn IIPGtI----VNADLNDEWVORALWFAlSEVNKAlKDDVYRRPLRVLRAROOlVGGVNVF~-FDVSVGRllClKSQPNL- -~-~-DlCAFHEbPELG-KKQLCSF-GlYEV-PWE.IRRSLVKSRC-QES 
hss EEDRIIEGGI~---VDADLNDERVORALHFVISEVNKAlEDEVVRRLLRVLRAREOlVGGVNVF~-FDlEVGRllClKSQPNL --~---OlCAFHEOPELO-KKOlCSF~OlYEV-PVE-DRNS~VDSRC-QEA 
bcs RLLGGL~---~EADVNfEGVOEALSFAVSEFNKRSNDAVOSRVVRVVRARKOVVSGNNVF~-LDVELGRllClKSQANL --~---OSCPFHNQPHLK-REKlCSF-GVYVV-PWN-WP!:!'~iKFSC-QD 
rcc GlSRPPPRLLGAP~---QEADASERGVORALDFAVSEVNKGSNDAVHSRAlQVVRAUKQLVAGlNVY~-LDVENGRlYClKSOlNL--~--- TNCPFHDGPHLN-RKALCSF-GIVSV-PWK-GYHTLTKSSC-KNA 
rcs LSCLGHFLGGI~---EKSSNEEEGASEALNVAVNEVNEKNSOLVLSRVVEVKOVQKOVVAGlKFF--FDVlLGKTlCLKlQGDL--~-~- INCPLNEEADOO-EHEFCSF-VVHDI-PWE-NYIVLLSSSC-HSI 
P.= IPGGL~---SPRDVlDPDVQEAAAFAVEKVNAGSKNDVVFKERRVV~AOSOVVSGVKVV--LNNELLKllCKKlVGRPKGVOElONCN~~LPPENOOEEllCRF-EVWSR-PWL-PSTSLYK 
Kinlnogen family (segment 1) 
hkl PESOS~--~EElDCNDKDLFKAVDAALKKVNSON9SNNOFVLYRlTEAYKlVGSDYFVS~-FKVSlkSGDC~VOSGKl -----WQDCEVKDAAKAAl--OECYA-YVGKR-SSY-KFSVATQl-C-QllP 
bkl OES-S~~--QEIDCNOQOVFKAVOAALlKVNSENKSGNOFVLVRllEVARNDNPDlFVS~-LKYQlKEGDCPFOSNKT --~--WQDCDVKDSAQAAl-~GCCTA-YVAKR-CYI(-KFSVAlQl-C-LllP 
rkl OEEGA~~--OELNCNDEYVFOAVDYALKKVNAELESGNOFVLVRVlEGYKKDGAElLVS~-FKYOlKESNCSVOSGLT ~-'--WODCDFKDAEEAAl--GECYl-YLCKK-EN--KFSVAYOl-C-NlYP 
rt11 OEEGA~~--OELNCNDETVFOAVDYALKRVWASLESGNOFVLVRVlEGYKKDGAElLVS--FKVOlKEGNVSVOSGLl- -~--WODCDFRDAEEAAl--GECYl-TLGUK~SN--KFSVATOl-C-NlYP 
i-t21 OEEGA~---OELNCNOEYVFOAVDYALKKV~AELESGNOFVLVRVlEGlKKDGAElLVS~-FK~OlKEGNVSVOSGLl --~--WQDCDFKDAEEAAl~~GECYl-YLEKR-RNN-KFSVAlOl-C-NlYP 
(ssgnnsnt 2) 
RkE AEGPVVYAOVDCLGCV-~~-HPlSlO§PDLEPlLR~GlOVFNNNlO~SSLFMLN~VKRAQRQVVAGLN~R~-llVSlVOlNCSKENFLF--~- LTPDCK--SLWNGDT-*GECYD-NAYID-IOL-RIASFSON-C-DIVP 
bk2 AEGPVVTAOVECLGCV~---HPISlKSPDLEPVLRYAlOVFNNNlSWSHLFDLKGVKRAQROVVSGWNVE--VNVSlAQlNCSKEEFSF--~- LTPDCK--SLSSGDl--GEClD-KARVD-VKL-RISSFSOK-C-DLVP 
rk2 CKGPKKlEEDLCVGCF~~--QPlPNDSSDLKPVLKNAVEHSNNNlKHlHLFALREVKSAWSOVVAGNNVK--llYSlVQTNCSKEDFPS--~- LREDCV-*PLPYGDH-*GECYG-WIAVD-IHN-TIAEFSPS-C-DLYP 
rtl2 GKGPKKlEEDLCVCCF~---QPlPHDSSOLKPVLKHAVEHSNUNlKHYHLFALREVKSAHSQVVAG~NVK--IlYSlVOlNCSKEDFPS--~- LREDCV--PLPYGDH--GECYG-MlllVD-lHN-lIAGFS9S-C~DLYP 
rt22 GKGPIVlNEYNCVGC14~---HPlSVDSPELGPVLKHAVEHFNNNlK~lRLFALGEVKSADROVVAGNNVQ~-llVSlVQlNCSKEDFPS---- LHEDCV--PLPSGDD*-GECKG-NAFVD-IHK-TIAGFSDS-C-EFYP 
(segmerlt 3) 
Rk3 GKDFVOPPYKICVGCP----RDlPlNSPELEETLY~lllULNAENNAlFVFKlONVRKARVOVVAGKKYF~-IOFVARSlYCSKESNEE~-~- LlESCE~-TKKLGOS-~LDCNA-EVVVV-PWE-KKIVPYVN-C-QPLG~ 
bk3 VKDFVQPPlRLCAGCP~---KPlPVDSPOtEEPLSHSIAKLNAEHOGAFVFKlOTVKKAlVGVVAGLKYS~-lVFIAREllCSKGSNEE~-~- LTKSCE--IWIHGOI~~L#CDA-NVVVV-PUE-EKVVPYVN-C-OPLGO 
rk3 GDDLFELLPKKCFGCP~~--LNlPVDSPELREALGHSlARLNAQRN~LFVF~lDYVKKAlSOVVAGlKYV~-lEFlARElNCSKlNllE---- LlADCE--lKHLGQS--LNCNA-NVVNR-PWE~NKVVPYVA-C-QALOM 
rtl3 GDDLFELLPKNCRGCP~~--RElPVOSPELWEALDHStARLNAOHNHlFVFKlDYVKKAYSOVVAGVlVV~-lEFlARElNCSKOSKlE--~- LlAOCE~-lKHLEPS--LNCNA-NVVNR~PWE-NKVVPlVR-C-OALDN 
rt23 GDDLFELLPEDCPGCP~~~-RNlPVDSPELKEALGHSlARlNAENNHYFVFkIDYVKKAYSOVVAGlKVV--lEFlARETNCSKESNAE .-.-LlADCE-.lKRLGQS~~LNCNA-NVVNR.PWE~NKVVPlVK-C~KVLDN 
Fig, 1. Alignment of amino acid sequences of stefins, cystatins and the homologous domains of kininogens. The alignmeW has been prepared main- 
ly by use of the ALIGN ptogramme [$l]. Numbering is according to the chicken cystatin sequence using the single letter code for amino acids. 
Key: (hsa) human stefin A; (rsa) rat cystatin 0~; (hsb) human stefin B; (rsb) rat cystatin 0; (orcl) oryzacystatin 1 PII; (WC111 OrYzacYstatin 11 1251; 
(drc) Drosophila cystatin [83]; (sac) sarcocystatin A [84], (hcc) human cystatin C; (cc) chicken cystatin; @cc) rat cystatin C WI; (rcs) rat CYstatin 
S [86]; (hcs) human cystatin S; (hsn) human cystatin SN; (hsa) human cystatin SA; (bee) bovine colostrum cystatin; (pat) African puff adder venom 
cystatin [87]; (hkl, hk2 and hk3) three human kininogen segments; (bkl, bk2 and bk3) three bovine kininogen segments; (rkl, rk2 and rk3 three 
rat kininogen segments; (rtll, rkl2, rkl3) three rat T-kininogen 1 segments; (rt21, rt22, rt23) three rat T-kininogen 2 sewents. References are 
in brackets. Other references are in [9,80] 1 
214 
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3. CYSTATIN FAMILY exception of the rat cystatin C [42], all other members 
of this family described so far are not glycosylated. 
The name cystatin was first used by Barrett [28] to 
describe an inhibitor that had been discovered and par- 
tially characterized from chicken egg-white of papain, 
ficin and other related cysteine endopeptidases [29]. 
When other protein inhibitors of cysteine proteinases 
were characterized and their amino acid sequences 
determined, it became apparent that they are related to 
chicken cystatin, and thus they are members of the 
cystatin superfamily [1 11. At the same time it was decid- 
ed that the second family within the cystatin superfami- 
ly may also be called the cystatin family. The main 
characteristic of the inhibitors of the cystatin family is 
the presence of two disulfide bonds located towards the 
carboxyl-terminus. They are composed of about 115 
amino acid residues with Mr of about 13 000. These 
proteins occur at relativgly high concentrations in many 
biological fluids such as human cystatin C in human 
seminal plasma (51 mg/l) and cerebrospinal fluid (5.8 
mg/I), and at lower concentrations in other fluids such 
as plasma, saliva and urine (reviewed in [9,14,30]). 
Chicken cystatin, the best known representative, was 
isolated as a mixture of two major isoelectric forms of 
identical amino acid sequences [3 1,321, a non- 
phosphorylaied form I with pI of 6.5 and a 
phosphorylated form 2 with p1 of 5.6 1331. Both 
variants can be further separated into full-length chains 
with 116 amino acid residues (Ser-forms) and several 
amino terminal-truncated forms including the Gly- and 
Ala-forms with 108 and 107 amino acid residues, 
respectively [34]. The shorter Gly-9- and the 
Ala- IO-forms (cystatin numbering) of chicken cystatin 
bind almost 10 OOO-fold weaker to papain compared to 
the longer forms (Ki = 6 PM) [34,35]. Chicken cystatin 
is a powerful protein inhibitor of papain (Ki = 5 x 
lo- I2 M) and other lysosomal cysteine proteinases 
(reviewed in [9,74]. Recently, the inhibitor has been 
cloned [36,37] and expressed [36]. The recombinant 
protein is active and similar in properties to those of the 
natural inhibitor. Chicken cystatin also has been 
crystallized and its three-dimensional structure deter- 
mined [38]. 
The most investigated inhibitor of human origin is 
cystatin C. It was isolated from serum of patients with 
autoimmune diseases [39]. The inhibitor occurs in 
several multiple forms with pIs in the alkaline pH 
range. When its partial amino acid sequence was deter- 
mined [39], we discovered that this inhibitor is identical 
to y-trace, a basic protein, of hitherto unknown 
biological function [40]. Due to its high degree of 
homology with chicken cystatin [31], we proposed that 
the newly discovered inhibitor of cysteine proteinases 
should be named human cystatin [19] and soon 
thereafter the name human cystatin C was suggested 
[41]. Cystatin C is also a very potent inhibitor of 
lysosomal cysteine proteinases and papain [9]. With the 
It was reported that the human cystatin C variant 
(former y-trace) is a major constituent of the amyloid 
fibrils in patients from Iceland with hereditary cerebral 
hemorrhage with amyloidosis 14431. The protein consists 
of 110 amino acid residues beginning at its 11 th amino- 
terminal residue Gly. It has an amino acid substitution 
glutamine for leucine at position 68 (in human cystatin 
C numbering) suggesting that a point mutation has oc- 
curred. Human cystatin C was cloned and expressed 
[44-461. The recombinant protein displayed full 
biological activity against its target enzymes [46]. 
There are many additional papers published by M. 
Abrahamson, A. Grubb and I. Olafsson indicating the 
biological importance of cystatin C. Due to the length 
of this minireview, it is not possible to include all of 
their important contributions. Several other cystatins 
were isolated from human saliva [47] and other species 
and their sequences determined (reviewed in [9]; see 
Fig. 1). 
4. KINI’NOGEN FAMILY 
Kininogens have long been known as the precursor 
proteins of the vasoactive kinins and as participants in 
the blood coaguiation cascade j48j. In addZion, their 
role in the acute phase response [49,50], inflammation 
[S 11, and the inhibition of papain-like cysteine pro- 
teinases [52-543 demonstrate their remarkable 
multifunctional nature, There are three distinct types of 
kininogens, designated as high molecular weight 
kininogen (II-kininogen) with && of about 120 000, low 
molecular weight kininogen (L-kininogen) with Mr of 
about 68 000, and T-kininogen (also known as ‘major 
acute phase protein’) with M, of about 68 000 (reviewed 
in [9,55-581). They are all single-chain proteins. They 
share the heavy chains preformed at the N-terminus and 
the consecutive kinin fragment, but differ in their light 
chain at the C-terminus. Both L- and I-I-kininogen also 
exist as oligomers, as well as monomers. Kininogens are 
acidic proteins with pI values for multiple isoelectric 
forms in the pH range 4.0-5.2. They have been found 
in plasma and other secretions of mammalian species. 
The concentrations of kininogens in human plasma are 
109-272 pg/ml for L-kininogen and 69-l 16 pg/ml for 
H-kininogen [59]. The inhibitory activities of 
kininogens are stable at neutral and alkaline pH range, 
but labile below pH 4.0. They are thermally stabIe (at 
9O’C) for short periods of time. 
The kininogens (L- and H-) are strong inhibitors of 
papain and cathepsin L and weaker inhibitors of 
cathepsin H and particularly cathepsin B (reviewed in 
[9,52,53,55,601). Strong inhibitory capacity against pa- 
pain and cathepsin L with T-kininogen was also found 
[49,61]. Our findings of the presence of cleavage pro- 
ducts from the kininogen heavy chain, in pathologic 
215 
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human plasma and synovial fluid [62,63], and human 
placenta [64] released by unknown proteinases, as 
smaller-sized inhibitors with M, of about 20 000 clearly 
suggested that proteolytic processing of kininogens can 
also occur in vivo, possibly affecting the coagulation 
system. Similar fragments were obtained when human 
L-kininogen was subjected to limited proteolysis with 
trypsin, chymotrypsin, elastase and other proteinases 
165,661. Several independent cleavage sites distinct from 
the typical kallikrein cleavage sites flanking the kinin 
region were found. All of the identified cleavage sites 
(in proteinase sensitive regions) cluster in two stretches 
of 11-12 residues of the kininogen heavy chain. By se- 
quence analysis three domains corresponding to the in- 
dividual cystatin-like domains (segments) were iden- 
tified and numbered l-3 from the N-terminus (see Fig. 
1). Only domain 1 was not inhibitory for cysteine pro- 
teinases. Domain 2 was an inhibitor of chicken calpain, 
papain and cathepsin L, whereas domain 3 did not in- 
hibit calpain, but inhibited papain and cathepsin L 
strongly. T-Kininogen (also called thiostatin) is an ex- 
ception to the general rule for kininogens, since it is not 
susceptible to kallikrein hydrolysis. Wowever, cathepsin 
D can liberate T-kinin (Hle-Ser-bradykinin) from T- 
kininogen [67,68]. Cathepsin D also inactivates the 
third domain of human kininogen and cystatin C [64], 
as well as human stefins [69] indicating that it has a 
biological role in the regulation of cysteine proteinase 
activity. Similarly, leucocyte elastase rapidly cleaves 
Val-lo-Gly-l l bond of human cystatin C, thus decreas- 
ing the inhibitory capacity of the truncated inhibitor for 
human cathepsins B and L by three orders of magnitude 
[69a]. 
fourth was close to the C-terminus of the T-kininogen 
light chain. 
In T-kininogen four proteinase sensitive regions were 
found [61J. Two were close to the junction between the 
heavy chain cystatin-like domains as noted in [65,66], 
the third was in the kinin-containing region, and the 
5. STRUCTURE OF CYSTATINS AND THE 
MECHANISM OF THEIR INTERACTION WITH 
CYSTEINE PROTEINASES 
The sequences of the three families of cystatin super- 
family: the stefins, the cystatins and the cystatin-like 
domains of t,he kininogens, are aligned in Fig. 1, accor- 
ding to the chicken cystatin numbering system. The 
presented alignment is based on the known tertiary 
structure of human stefin B [24] which confirms the 
relationship between the stefin and cystatin families. In 
particular, conserved residues of stefin B occur in posi- 
tions equivalent to those of chicken cystatin. However, 
there are also some important differences in alignment 
which are difficult to predict. Thus, the published se- 
quence alignment [9,55] has been found to be incorrect, 
largely due to a deletion of 23 residues with respect to 
the chicken cystatin sequence, which is a source of a 
high gap penalty in most alignment algorithms. The se- 
quences (Fig. 1) are most highly conserved between 
residues 53 and 57 (QVVAG region) in the stefins and 
in the second and the third domains of the kininogens. 
The corresponding region in the cystatin family shows 
that only Gin-53 and Gln-57 are highly conserved. The 
only other residue conserved in all of the inhibitory 
cystatins (but not in the non-inhibitory first domain of 
the kininogens) is Gly-9, once proposed to be a part of 
a substrate-like inhibitory reactive site of cystatins [35]. 
Fig. 2 is a ribbon-like stereo representation of the 
chicken cystatin molecule based on the crystal structure 
[38]. The molecule consists mainly of a straight five 
turn a-helix, a five stranded antiparallel P-pleated sheet 
which is twisted and wrapped around this a-helix, and 
an appended segment of partial a-helical geometry. The 
Fig. 2. Ribbon-like representation (made with RIBBON, kindly provided by Dr. Priestle) of chicken egg-whitecystatin, a-Helical segments, extend- 
ed P-strands and irregular intervening segments are shown as regularized helical and arrow-like elements and connecting laces, The view is approx- 
imately along the wedge-shaped edge placed at the left upper side, with (from back to front) arnino4erminus (from Gly-9 onwards), first and second 
hairpin loop. The carboxy-terminus is at the bottom left, the appending helix on the right-hand side. 
216 
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Fig. 3. Scheme of the proposed ‘trunk model’ for the interaction of 
chicken egg-white cystatin (cew cystatin) and papain. 
peptide segment from Gln-53 to Gly-57 folds into a 
$ht ‘first’ &hairpin loop which is bn opposite sides 
flanked by the amino-terminal segment and by a ‘se- 
cond’ P-hairpin loop that contains Pro-Trp residues. 
These residues are highly conserved in the cystatin fami- 
ly and the third domain of the kininogens. Both hairpin 
loops and the N-terminus form a hydrophobic wedge- 
shaped ‘edge’ which is highly complementary to the ac- 
tive site cleft of papain as shown by docking ex- 
periments 1381. The essential interactive elements of this 
hypothetica! complex are shown in Fig. 3 and discussed 
in detail in [34,38,70,71]. In this ‘trunk model’, both 
the first and the second hairpin loops have precisely the 
appropriate shape and size to fill the more open part of 
the active site cleft of papain which represents the 
S1 ‘82 subsites. The amino-terminal segment of 
cystatin (Gly-9-Ala-lo) is directed towards the 
substrate subsite S2, but in an inappropriate conforma- 
tion and too far away to be attacked by the reactive site 
Cys-25. Due to the rigid positioning of’ Ala-10 in 
cystatin away from Cys-25 in papain, a cleavage of the 
Gly-9-Ala-10 bond is impossible. The important role of 
Trp-104 as part of the proteinase-binding site in the 
second hairpin loop was recently confirmed [72-741. 
The proposed model was recently verified by the 
crystallized stoichiometric complex of human stefin B 
and papain [24]. The conserved residues form a tripar- 
tite wedge, which penetrates into the uauain active site 
as proposed earlier 1381. The main interactions are pro- 
vided by the amino-terminal ‘trunk’ and the first hair- 
pin loop containing the highly conserved QVVAG 
region, with minor contributions coming from the 
second hairpin loop. The carboxyl-terminus provides 
an additional interaction with respect to chicken 
cystatin. The data presented clearly show that the 
cystatin inhibition mechanism differs substantially 
from the standard mechanism generally observed for 
serine proteinase-inhibitor complexes [75]. 
Structural analysis of stefins, cystatins and three do- 
mains of the kininogens revealed that they share exten- 
sive sequence homology, enough to be classified as 
members of one superfamily [ll]. A scheme for the 
evolution of mammalian cystatins was proposed predic- 
ting that the kininogens arose from the cystatins by gene 
triplication via intermediates containing two cystatin- 
like structural domains [76]. From difference matrix 
analyses a phylogenetic dendrogram was constructed 
that attempts to depict the progress of evolution for the 
cystatins [9,77]. The finding that CYZ-HS glycoprotein 
[78] and histidine-rich glycoprotein (both inactive as 
proteinase inhibitors) contain two cystatin-like domains 
initiated further studies of the evolutionary relation- 
ships for this superfamily. Most recently a new scheme 
for the evolution of the cystatin superfamily was pro- 
posed [go] based on the numbers of copies of cystatin- 
like domains and the presence or absence of disulfide 
bonds and following the evolution of the superfamily 
among four main lineages. Continuing investigations of 
the cystatins from a variety of species of animal and 
plant origins will undoubtedly lead to a more definitive 
scheme for the evolution of these interesting and 
physiologically important proteins. 
6. CONCLUSIONS 
In the field of cystatin and their target enzymes we 
have achieved in the last decade enormous progress 
concerning their structures, functions and evolutionary 
relationships. There is also rapidly growing information 
about the importance of these biologically active 
substances in many pathological events as inflamma- 
tion, muscle dystrophy, Alzheimer’s disease, multiple 
sclerosis, viral diseases, hereditary diseases, tumor 
malignancy and other health-related disorders. The 
potential for cystatins playing a roie in host plant 
resistance is also apparent. Therefore, further studies 
are required to obtain more knowledge of the 
biochemistry and molecular biology of cysteine pro- 
teinase and their inhibitors, in general, in order to better 
understand protein degradation under normal and 
pa.thological conditions. Further advances in the struc- 
ture and function of cystatins 
design of new therapeutic and 
might be useful for the 
pest contror agents. 
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